Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesFrom All AnglesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Niraparib Showcases Improved Health-Related QOL, Reduced Pain Burden in mCRPC

      May 5, 2022
      By Gina Mauro
      Article
      Conferences|ONS Annual Congress

      Niraparib improved or maintained health-related quality of life, pain intensity, and pain interference in patients with advanced or metastatic castration-resistant prostate cancer.

      Niraparib (Zejula) improved or maintained health-related quality of life (HRQOL), pain intensity, and pain interference in patients with advanced or metastatic castration-resistant prostate cancer (mCRPC), including those with BRCA gene alterations, according to the final analysis of the GALAHAD trial (NCT02854436) that was presented at the 47th Annual Oncology Nursing Society (ONS) Congress.

      “In patients with advanced mCRPC and HRR gene alterations, niraparib improved or maintained overall HRQOL measures as assessed by the [Functional Assessment of Cancer Therapy-Prostate] total score, and pain intensity and pain interference as measured using the [Brief Pain Inventory-Short Form],” lead study author Minh Tran of Kaiser Permanente said in a virtual poster presentation during the meeting. “These data provide valuable information for clinicians and nurses to consider while caring for patients receiving niraparib for advanced prostate cancer.”

      The open-label, international, phase 2 GALAHAD trial evaluated single-agent niraparib in patients with mCRPC and HRR gene alterations who progressed on prior taxane-based chemotherapy and androgen receptor inhibition. Niraparib was given orally at 300 mg daily and patients were stratified by the type of HRR gene alteration (BRCA cohort [BRCA1 or BRCA2]) or other HRR cohort (ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2).

      Previous data from GALAHAD, which were published in The Lancet, showcased meaningful clinical activity.2 At a median follow-up of 10.0 months (interquartile range, 6.6-13.3), evaluable patients with BRCA alterations and measurable disease (n = 76) achieved an objective response rate (ORR) of 34.2% (95% CI, 23.7%-46.0%) with the PARP inhibitor. In this cohort, 3% experienced a complete response (CR), and 32% had a partial response (PR).

      Among evaluable patients with non–BRCA-altered measurable disease (n = 47), niraparib produced an ORR of 10.6% (95% CI, 3.5%-23.1%); here, no CRs were achieved, and 11% experienced PRs.

      In the findings presented at the ONS Congress, investigators reported on the HRQOL outcomes, which was a prespecified exploratory end point in GALAHAD. Specifically, they evaluated the effect that niraparib had on overall HRQOL, pain intensity, and pain interference in patients with advanced mCRPC and HRR gene alterations.

      Patient-reported outcomes (PROs) were assessed in all patients who had completed the baseline assessment and at least 1 postbaseline assessment. HRQOL was assessed on day 1 of cycles 3, 5, 7, and 10 with the following PROs:

      1. Functional Assessment of Cancer Therapy-Prostate (FACT-P), which assessed patient’s self-reported functional status, well-being, and prostate cancer–related symptoms;
      2. Brief Pain Inventory-Short Form (BPI-SF), which measured pain intensity and interference—which includes how much pain interferes with recent daily functions, such as general activity, walking, work, mood, enjoyment of life, relations with others, and sleep;
      3. Baseline HRQOL changes were compared for BRCA vs other HRR patients through a mixed-effects model for repeated measures (MMRM).

      PROs were categorized by improved (FACT-P, change from baseline [CFB] ≥10; BPI-SF, CFB ≤-0.5 standard deviation [SD]), stable (FACT-P, -10 < CFB <10; BPI-SF, -0.5 SD < CFB <0.5 SD), or worsened (FACT-P, CFB ≤-10; BPI-F, CFB ≥0.5 SD).

      The median time to first deterioration in PROs was estimated by a Kaplan-Meier technique and was determined by meaningful change threshold values.

      A total 221 patients were eligible for analysis, and most patients completed PRO assessments from baseline through cycle 10. Demographic and baseline characteristics were similar between the 2 cohorts in the intent-to-treat population.

      In the BRCA cohort (n = 142), the median age was 67.0 years (range, 46-86) and patients had an ECOG performance status (PS) of 0 (33.8%), 1 (54.9%), or 2 (11.3%). A total 53.5% of patients had measurable disease status, a mean FACT-P total score of 21.5, a mean BPI-SF pain intensity score of 2.3, and a BPI-SF pain interference score of 2.7 at baseline.

      In the other HRR cohort (n = 81), the median age was 70.0 years (range, 52-88) and the ECOG PS was 0 (22.2%), 1 (58.0%), or 2 (19.8%). Here, 58.0% of patients had measurable disease status and the mean FACT-P total score at baseline was 22.1, the BPI-SF pain intensity score was 2.3, and the BPI-SF pain interference score was 2.5.

      Findings showed that patients generally demonstrated stable or improved overall HRQOL in FACT-P MMRM, and overall HRQOL was improved in the BRCA cohort following 3 cycles of niraparib (6.03). In the other HRR cohort, patients overall remained stable until cycle 10 (–5.10).

      Additionally, patients in the BRCA cohort were more likely to experience clinically meaningful improvements in overall HRQOL vs those in the other HRR cohort. In distributions of FACT-P total change from baseline categories, this was seen in baseline to cycle 3 (OR, 2.40), baseline to cycle 5 (OR, 4.42), baseline to cycle 7 (OR, 2.01), and baseline to cycle 10 (OR, 1.69).

      Furthermore, patients demonstrated stable or improved BPI-SF MMRM pain intensity scores, with rapid reduction reductions in scores seen in both cohorts. While those in the BRCA cohort experienced greater early pain relief (cycle 3, –1.06; cycle 5, ­–0.88), the mean pain intensity reductions were similar between cohorts by cycle 7 (BRCA, –0.61 vs other HRR, –0.53). Additionally, more patients in the BRCA cohort showed stable or improved pain intensity score compared with those in the other HRR cohort through to cycle 7.

      Investigators also looked at BPI-SF MMRM pain interference scores. Both cohorts experienced rapid reductions in pain interference, but greater reductions in pain interference were seen in the BRCA cohort vs the other HRR cohort up to cycle 10. Regarding distribution of BPI-SF pain interference change from baseline categories by cohort, more patients in the BRCA cohort were stable or improved for most cycles vs the other HRR cohort.

      Investigators also evaluated a Kaplan-Meier plot of time to deterioration in the FACT-P total score. The median time to deterioration in the FACT-P total score was longer in the BRCA cohort at 8.31 months vs 3.71 months in the other HRR cohort. With regard to the Kaplan-Meier plot of time to deterioration in pain interference subscale, most patients overall did not experience clinically meaningful worsening of pain intensity or pain interference.

      References

      1. Tran M, Olivier K, Liu Y, et al. Effects of niraparib on health-related quality of life in the final analysis of the GALAHAD study in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations. Presented at: 47th Annual Oncology Nursing Society Congress; April 27-May 1, 2022; Anaheim, CA. Abstract P392.
      2. Smith MR, Scher HI, Sandhu S, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet. 2022;23(3):362-373. doi:10.1016/S1470-2045(21)00757-9

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      Photo of a man wearing glasses and a suit in front of a blue background
      Image of a woman with gray hair and glasses in front of a blue Oncology Nursing News background
      Photo of a woman with blond wavy hair wearing a blazer in front of a blue Oncology Nursing News background
      Photo of a woman with shoulder-length blond hair in front of an Oncology Nursing News backdrop
      Image of a woman with white hair in front of an Oncology Nursing News blue background
      Image of a man in a suit standing in front of a blue Oncology Nursing News backdrop
      Man standing in front of Oncology Nursing News-branded backdrop
      Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
      Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
      Related Content

      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      June 15th 2023
      Podcast

      Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.


      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 18th 2025
      Article

      Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.


      The Vitals

      Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

      Lindsay Fischer
      June 1st 2023
      Podcast

      Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.


      Photo of acupuncture needles resting in a bowl

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Ariana Pelosci
      April 22nd 2025
      Article

      Image of blood with leukemia cells present

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Chris Ryan
      April 21st 2025
      Article

      Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.

      Related Content

      Graphic of a kidney with a tumor

      KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC

      Kyle Doherty
      July 21st 2025
      Article

      Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.


      The Vitals

      Lauren Mahon Offers Nurse Perspectives on PARP Inhibitors As Ovarian Cancer Maintenance Therapy

      Lindsay Fischer
      June 15th 2023
      Podcast

      Lauren Mahon, MSN, FNP-BC, breaks down what oncology nurses should know about PARP inhibitors in ovarian cancer.


      Photo of a main holding his lower back in pain with a graphic of a kidney overlaying

      Opinion: IV Magnesium May Help Prevent Cisplatin-Induced AKI

      Amanda Brink, DNP, APRN, FNP-BC, AOCNP
      July 18th 2025
      Article

      Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.


      The Vitals

      Seth Eisenberg Discusses New Methods of Reducing Hazardous Drug–Contaminated Toilet Aerosols in Hospital Setting

      Lindsay Fischer
      June 1st 2023
      Podcast

      Seth Eisenberg, ASN, RN, OCN, BMTCN, emphasizes the importance of reducing nurse exposure to hazardous drugs—and ongoing research efforts to improve nursing safety.


      Photo of acupuncture needles resting in a bowl

      Acupuncture Use in BC Predicted by Social Determinants of Health

      Ariana Pelosci
      April 22nd 2025
      Article

      Image of blood with leukemia cells present

      Variability Found in PROs, Gene Expression During AML Induction Chemo

      Chris Ryan
      April 21st 2025
      Article

      Gene expression in peripheral blood as well as patient-reported outcomes differed for those with acute myeloid leukemia undergoing induction chemotherapy.

      Latest Conference Coverage

      Sonrotoclax/Zanubrutinib Generates Durable Response in R/R MCL

      Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts

      Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer

      Understanding How On-Target and Off-Target ADC Toxicities Work

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.